The Biomarker Discovery Platform provides infrastructure for the detection and quantification of biomarkers, such as proteins, peptides and nucleotides, in any biological fluids and samples. The platform provides not only the facility and expertise to analyse known biomarkers, but also the opportunity to discover and develop novel biomarkers that are of clinical utility in the diagnosis, prognosis, and monitoring of disease conditions. The Platform further affords the opportunity to study mechanisms of disease progression and therapeutic responses.
We have developed and validated sensitive and specific assays for many biomarkers and validated assay protocols with significant cost savings and sample savings. Assays have been performed for over several thousand samples of several major clinical trials with results published in high impact journals.
We work with both internal and external groups on collaborative projects. Development of additional capabilities is ongoing, and we are happy to discuss project-specific needs.
For more information, contact:
Associate Professor Bing Wang
Head, Biomarker Discovery
E: bing.wang@baker.edu.au
Analytical platform
Peptide and protein biomarkers
Peptide or protein biomarkers are mostly analysed with immunoassays. There are several formats available for immunoassay (sandwich or homogenous) including immunoassays with ELISA and homogenous immunoassays with AlphaLISA or HTRF using high-end multimode plate reader (PHERAstar FSX, BMG); and Multiplex assays: xMAP technology platform using Luminex 200.
Nucleotides Markers (small RNA, miRNA, and DNA)
Circulating non-coding nucleotides such as small RNA, micro RNA, ncR/DNA & long ncR/DNA can be extracted with QiaCube HT (Qiagen) high throughput extraction system and analysed with qRT-PCR, Open Array and xTAG, using QuantStudio 12KFlex qPCR (Applied BioSystem) capable of running Open Array, 96-well and 384 well-PCR plates.
Location
Baker Heart and Diabetes Institute
75 Commercial Road, Melbourne
Victoria 3004 Australia